Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05540717 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
A Phase 3 study, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 555
- Enrollment target
NCT05540717 is a Phase 3 study that has completed, run by Allergy Therapeutics. The registered enrollment target is 555 participants.
The verdict
NCT05540717, a Phase 3 study, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 555 participants
- Enrollment target
Study Summary
The PQGrass306 (G306) clinical trial is the pivotal Phase III efficacy clinical trial of PQ Grass. The aim of the G306 pivotal clinical trial is to confirm the efficacy and safety of the optimal effective dose of PQ Grass 27600 SU. This will be determined through the measurements of the effect of PQ Grass on the symptoms of seasonal allergic rhinitis (SAR)/rhinoconjunctivitis and the use of relief medications to control these symptoms during the peak grass pollen season (GPS).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PQ Grass
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2022-10-11 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05540717
The ClinicalTrials.gov registry entry for NCT05540717 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 555 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05540717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05540717 about?
NCT05540717 is a clinical study titled "Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen". The PQGrass306 (G306) clinical trial is the pivotal Phase III efficacy clinical trial of PQ Grass. The aim of the G306 pivotal clinical trial is to confirm the efficacy and safety of the optimal effective dose of PQ Grass 27600 SU. This will be determined through the measurements of the effect of P...
What is the current status of trial NCT05540717?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 555 participants. The study started on 2022-10-11. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT05540717?
The interventions under investigation include: Placebo (BIOLOGICAL), PQ Grass (BIOLOGICAL).
Who is sponsoring clinical trial NCT05540717?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.